Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €19.26 EUR
Change Today +0.01 / 0.05%
Volume 0.0
L3Q On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (L3Q) Snapshot

Open
€19.09
Previous Close
€19.25
Day High
€19.35
Day Low
€18.82
52 Week High
07/17/15 - €21.54
52 Week Low
10/13/14 - €9.36
Market Cap
662.2M
Average Volume 10 Days
32.5
EPS TTM
--
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OSIRIS THERAPEUTICS INC (L3Q)

osiris therapeutics inc (L3Q) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (L3Q) Details

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. It markets and distributes its products directly to hospitals, clinics, and physician offices as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

211 Employees
Last Reported Date: 03/20/15
Founded in 1992

osiris therapeutics inc (L3Q) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $510.0K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $241.4K
Chief Medical Officer
Total Annual Compensation: $28.6K
Vice President and General Manager of Wound C...
Total Annual Compensation: $328.2K
Vice President of Finance
Total Annual Compensation: $27.6K
Compensation as of Fiscal Year 2014.

osiris therapeutics inc (L3Q) Key Developments

Osiris Therapeutics, Inc. Approves the Amendments to Articles of Incorporation

Osiris Therapeutics, Inc. approved the amendments to articles of incorporation, at the 2015 annual meeting of stockholders held on June 10, 2015.

Osiris Therapeutics, Inc. Evaluates the Establishment of an International Subsidiary

Osiris Therapeutics, Inc. announced that it is evaluating the establishment of an international, ex-U.S. subsidiary in recognition of its expanding research and commercial business operations. The company is currently evaluating different locations, including United Kingdom, Singapore and Switzerland.

Osiris Therapeutics, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Osiris Therapeutics, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. The company reported product revenues during the first quarter of 2015 were $21.0 million, compared to $10.1 million during the first quarter of 2014, an increase of 109%. Income from operations of continuing operations was $1,843,000 compared to loss from operations of continuing operations of $615,000 for the same period a year ago. Income from continuing operations, before income taxes was $1,989,000 against loss from continuing operations, before income taxes of $741,000 a year ago. Income from continuing operations was $1,377,000 or $0.04 per basic and diluted share against loss from continuing operations of $611,000 or $0.02 per basic and diluted share a year ago. Net profit was $1,377,000 or $0.04 per basic and diluted share against net loss of $1,365,000 or $0.04 per basic and diluted share a year ago. Net cash used in operating activities was $359,000 against $5,570,000 a year ago. Purchases of property and equipment were $345,000 against $127,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
L3Q:GR €19.26 EUR +0.01

L3Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.16 USD -0.07
CryoLife Inc $10.95 USD -0.06
Derma Sciences Inc $7.15 USD +0.02
Organovo Holdings Inc $3.38 USD +0.01
Vitrolife AB kr174.00 SEK +1.00
View Industry Companies
 

Industry Analysis

L3Q

Industry Average

Valuation L3Q Industry Range
Price/Earnings 100.0x
Price/Sales 10.3x
Price/Book 8.5x
Price/Cash Flow 769.7x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit www.osiristx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.